ABSTRACT
INTRODUCTION
Twin-twin transfusion syndrome (TTTS) is a unique pathology exclusive to pregnancy involving monochorionic twins, in which unbalanced transfusion across the placental vascular anastomoses leads to amniotic fluid volume imbalance between the twins 1 . In severe TTTS, the mortality rate is as high as 90% if untreated 2, 3 . Even with treatment, TTTS is still associated with an increased risk of perinatal mortality and morbidity compared with in uncomplicated monochorionic pregnancy, with neurological and cardiac complications reported, as well as a significant risk of preterm birth and its associated complications [2] [3] [4] [5] [6] [7] [8] .
Treatment options include fetoscopic laser surgery, amnioreduction, septostomy, expectant management and termination of pregnancy. Fetoscopic laser surgery now forms the mainstay of treatment and different techniques have also been compared 9 . Given the high potential for morbidity and mortality in TTTS, there is a need for robust guidance on the safest course of management, particularly in the refinement of new treatment techniques.
The importance of standardizing randomized controlled trial methods has been recognized. However, the selection, collection and reporting of outcomes have received less attention, despite being critical steps in the design of randomized trials 10 . Such outcomes should reflect both beneficial and harmful effects and be relevant to clinical practice and key stakeholders, including patients, healthcare professionals and researchers. Evidence synthesis can be further hampered by different methods of measurement or definition, even when outcomes have been collected consistently across trials. For example, childhood neurodevelopmental impairment has been defined using different combinations of clinical signs and cognitive assessments, performed using a range of tools, by different professionals and at different ages in childhood.
There is no consensus amongst key stakeholders on which outcomes should be collected and reported in studies on TTTS treatments. The first step in developing a core outcome set for TTTS requires evaluation of the reporting of outcomes and outcome measures. The objective of the present study was therefore to assess the consistency of outcome reporting, including the adequacy of information pertaining to definition and measurement, among randomized trials and observational studies evaluating treatments for TTTS.
METHODS

Protocol, eligibility criteria, information sources and search
The protocol for this systematic review was registered prospectively on PROSPERO (International Prospective Register of Systematic Reviews; registration number: CRD42016043999) 11 . The reporting guidelines outlined by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement were followed 12 . The Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE and MEDLINE were searched from inception to August 2016 using medical subject heading (MeSH) descriptors including 'twin-twin transfusion syndrome', 'twin-to-twin transfusion syndrome' and 'fetofetal transfusion' (Table S1 ). We included all randomized trials and observational studies reporting outcome following treatment for TTTS in monochorionic-diamniotic twin pregnancy and monochorionic-triamniotic or dichorionic-triamniotic triplet pregnancy. Case reports, review articles, metaanalyses and systematic reviews were excluded. No restriction on language or publication date was applied and articles were translated when necessary.
Study selection, data collection and data items
Two authors (H.P. and O.U.) screened independently all titles and abstracts in the search results. Studies were excluded if they did not fit the eligibility criteria and full texts were obtained for studies that were obviously eligible and those that could not be excluded based on title or abstract alone. These full-text articles were reviewed critically for eligibility by two authors and any discrepancies were discussed and resolved with a third author.
Data were extracted from eligible studies using a standardized data collection tool. Collected variables included year of publication, publishing journal, study design, setting, participants, treatments, stage of TTTS and funding source (if applicable). Impact factors were obtained from the International Scientific Institute's Impact Factor List. Quality assessment was performed for each study. For randomized trials, the Jadad scoring system was used and for observational studies, the Newcastle-Ottawa scoring system was used 13, 14 . The size of the study was classified based on either maternal or childhood participants, depending on the subject of the study. Due to the large number of relatively small single-center retrospective observational studies, we decided to include all randomized controlled trials and the 94 largest observational studies in the analysis. After full-text review, we did not feel that including more studies would add to the variety of recorded outcomes.
Primary and secondary outcomes were recorded, as well as their definition and instruments of measure. Outcomes listed as 'collected variables' were considered and included if they were documented clearly in the abstract or methods section and reported in the results section. Outcomes listed for the first time in the results section without any clear justification were not included. An inventory of outcomes was produced and these were organized into the following categories: fetal outcomes, offspring mortality, neonatal outcomes, early childhood outcomes, maternal outcomes and operative complications.
RESULTS
Study selection and characteristics
The search identified 1209 articles. Forty-six duplicates were removed and 898 articles were considered not to meet inclusion criteria after title and abstract screening. Duplicates were defined as articles with the same title, authors and publishing journal and year. Of the 898 articles that did not meet inclusion criteria, 387 were unrelated to TTTS, 483 were not an intervention study (e.g. review, comment, case report) and in 28 cases the narrative did not fit the inclusion criteria (e.g. the paper did not report a discernible outcome). Of the 265 articles identified for full-text review, 35 were excluded as either they did not meet inclusion criteria (n = 32) or the full text could not be obtained (n = 3). Two hundred and thirty studies were therefore deemed eligible after full-text review. From these, all randomized trials (n = 6) 9, [15] [16] [17] [18] [19] and the largest observational studies (n = 94) were selected for analysis ( Figure 1 ). There were 13 case-control studies, 32 prospective cohort studies and 49 retrospective cohort studies. The 100 included studies reported data on 20 071 maternal participants and 3199 children. 
Synthesis of results
Six different treatments were evaluated: fetoscopic laser surgery (95 studies; 95%); amnioreduction (15 studies; 15%); septostomy (one study; 1%); expectant management (five studies; 5%); selective feticide (two studies; 2%); and delivery (one study; 1%). Eighty of the studies evaluated fetoscopic laser surgery alone, three of which compared different techniques of fetoscopic laser surgery; two studies compared the Solomon technique with the standard technique and one compared different uterine entry techniques (sheath and trocar, cannula and trocar or cannula and Seldinger). Three studies evaluated adjuncts to fetoscopic laser surgery, including nifedipine therapy, cervical cerclage and laparoscopic guidance. One study evaluated amnioreduction alone and the remaining 16 compared two or more treatments, one of which included the adjunct of digoxin therapy with amnioreduction. Full details of the studies and their treatments are shown in Table S2 . Included trials reported 62 different outcomes, organized within six domains: six fetal outcomes, seven offspring mortality outcomes, 25 neonatal outcomes, six early childhood outcomes, eight maternal outcomes and 10 operative outcomes (Table 1 ). Regarding quality assessment, two of the randomized trials scored four out of five on the Jadad score and the remainder scored three out of five. None of them involved blinding due to the nature of the treatments. Of the observational studies, only seven scored eight stars out of nine, nine scored seven stars, 38 scored six, 30 scored five and 10 scored four (Table S2) .
Concerning fetal outcomes, only 17 (17%) studies reported recurrence of TTTS (4206 participants; 21.0%) and others were reported even less frequently. Offspring mortality was the most reported group; however, there was inconsistency in the reported outcomes. Thirty-one (31%) studies reported live birth (5219 participants; 26.0%), 31 (31%) reported intrauterine death (6376 participants; 31.8%), 49 (49%) reported neonatal mortality (8216 participants; 40.9%) and 17 (17%) reported perinatal mortality (3172 participants; 15.8%). Neonatal outcomes were reported with varying frequency, with 33 (33%) studies reporting gestational age at delivery (5583 participants; 27.8%), 16 (16%) studies reporting intraventricular hemorrhage (3430 participants; 17.1%), six (6%) studies reporting necrotizing enterocolitis (1023 participants; 5.1%) and four (4%) studies reporting respiratory distress syndrome (620 participants; 3.1%). Early childhood outcomes were not commonly reported, with only 19 studies reporting on outcome beyond the neonatal period. Of these, 13 (13%) reported neurodevelopmental impairment and 11 (11%) reported cerebral palsy (1868 (9.3%) and 1459 (7.3%) participants, respectively).
The most commonly reported maternal outcome was premature rupture of membranes, which was reported in 31 (31%) studies (6057 participants; 30.2%). Operative complications were reported poorly, with only six (6%) studies reporting hemorrhage (914 participants; 4.6%) and one (1%) study reporting pain (175 participants; 0.9%). The full range of reported outcomes is shown in Table 1 . When considering the six randomized controlled trials and the 20 largest observational studies, 38% reported neonatal mortality, 23% reported premature rupture of membranes and 12% reported neurodevelopmental impairment in childhood (Table S3) .
There was variation in the definitions used for reported outcomes. For neonatal mortality/survival, five different definitions were found, but in 47% of studies in which it was reported as an outcome, no definition was given. Seven different definitions were identified for premature rupture of membranes and eight for childhood neurodevelopmental impairment. The full range of variation is demonstrated in Table 2 .
DISCUSSION
Summary of main findings
We have found wide variation and inconsistencies in the reporting of maternal and offspring outcomes. Of six randomized controlled trials and 94 observational studies, reporting data from 20 071 maternal participants, fewer than a third reported live birth or intrauterine death as an outcome. Whilst 49% of studies reported neonatal mortality/survival as an outcome, there were five different definitions used and almost half of these studies did not define it. Neonatal morbidity was reported poorly, with only four studies reporting as an outcome respiratory distress syndrome, a common morbidity associated with prematurity. Only 19 studies were designed for follow-up beyond the neonatal period and 13 of these reported on childhood neurological outcome. Despite the mainstay of treatments for TTTS being surgical, maternal and operative outcomes were not commonly reported, with hemorrhage reported by only 6% of studies and pain by 1%.
Strengths and limitations
The strengths of this study are in its robust methodology. Following prospective registration, with predetermined outcomes, an independent search was performed without limits on date or language and we translated articles when necessary in order to be as inclusive as possible. Study selection and data extraction were performed independently by two authors to limit bias. This study is limited in its ability to garner patient-important outcomes, which may not be best evaluated in randomized controlled trials or observational studies. Further qualitative research, such as structured interview-based studies, is required to overcome this. To reduce bias further in the review process, we could have blinded the reviewers to details of the articles, such as authors, year of publication and publication journal. By limiting the final analysis to randomized trials and the 94 largest observational studies, we may have missed out on outcomes reported by smaller studies, which were not reported by larger ones. However, with the inclusion of 62 outcomes across seven domains, we feel that this review is reflective of current studies of treatment for TTTS. Our study may underestimate consistency in outcome reporting due to our methodology of reporting all studies individually even if they were from the same center. It is possible that different publications were used to report different outcomes from the same centers. Similarly, by including only outcomes and recorded variables defined clearly in the abstract and methods section, we may have under-reported some outcomes if they were only mentioned for the first time in the results section. Our rationale for this is that any outcomes that the researchers planned to report would normally be outlined in advance. We had a consistent approach to all reviewed studies and feel we have highlighted that different studies prioritize different outcomes, resulting in wide variation in outcome reporting.
Interpretation of findings
Our search identified only six randomized controlled trials reporting outcome after treatment for TTTS, reflecting the fact that, due to the relatively low prevalence of this condition, it is difficult to perform large, good-quality trials. With this in mind, it is of paramount importance that studies collect data on relevant outcomes that can be interpreted in relation to existing literature and for which results can be easily compared 114 . Previous studies have also found variation and inconsistency in the reporting of outcomes in different areas of women's health, including pre-eclampsia, preterm birth and endometriosis [115] [116] [117] [118] [119] . One possible reason for this diversity in outcome reporting in TTTS is the emergence of fetoscopic laser surgery, a new leading treatment, over the last 20 years. As the risk of fetal mortality in TTTS is so high, pioneers of this treatment focused primarily on survival to birth as an outcome, with less regard for other outcomes that may be considered important by stakeholders. The fact that many different centers were publishing their results independently as relatively small observational studies probably compounded this effect.
With an improving rate of survival to birth, there is now increased interest in neonatal and longer term morbidity for surviving children and, as with any treatment for fetal disease, consideration should also be given to the effects on the mother. This systematic review highlights that, to date, these outcomes have not been reported consistently, with only 19 of the 100 studies designed to obtain outcomes beyond the neonatal period. We feel that any center performing treatment for TTTS should have access to neonatal outcomes, yet, with the exception of neonatal mortality, these were not commonly reported. Outcomes such as necrotizing enterocolitis are likely to be considered important by parents. This issue is not unique to TTTS; in a systematic review of outcome reporting in preterm birth 116 , only one (1%) randomized trial reported composite morbidity in the neonatal period or at follow-up and none reported on maternal morbidity and mortality. Similarly, in a systematic review of outcome reporting in pre-eclampsia 115 , the authors found that only 6 (7.6%) randomized trials reported childhood outcomes. Bias may be introduced right from the start in the selection of primary outcomes, as researchers are influenced by factors including sample size requirement, time until an outcome can be reported and cost. This can lead to more accessible but less informative outcomes being selected 120 . The Core Outcomes in Women's and Newborn Health (CROWN) initiative aims to facilitate consistent recording and reporting of outcomes by working closely with journals, researchers, funders and patients to develop core outcome sets for specific diseases 121, 122 . Several core outcome sets are in development across obstetrics, including for gastroschisis, fetal monitoring and stillbirth 123 . The Core Outcome Measures in Effectiveness Trials (COMET) initiative suggests three stages to developing a core outcome set: (1) identifying potential core outcomes; (2) determining core outcomes using robust consensus methods engaging key stakeholders; and (3) determining how core outcomes should be measured 124 . In line with the CROWN and COMET initiatives, we have described previously our intention to develop a core outcome set for TTTS and the inventory of outcomes identified by this systematic review will be entered into a Delphi method for the second stage of the process. Key stakeholders, including researchers, clinicians and patients, will be invited to participate in this consensus-forming exercise 125 . This process has worked successfully in the development of core outcome sets for other related conditions, including abortion, pre-eclampsia, neonatal care and endometriosis [126] [127] [128] [129] . For example, regarding preterm birth, 174 participants from five stakeholder groups reviewed and scored 31 outcomes via a Delphi survey. The final core outcome set consisted of 13 outcomes for which consensus was met 130 .
Conclusion
Most studies reporting outcome following treatment for TTTS are observational in nature and report many different outcomes with varying definitions. These inconsistencies contribute to an inability to compare, contrast and combine results and inform decision making in a clinical context. Developing a clinically relevant core dataset for implementation in future TTTS trials could help to address these issues.
SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article: Table S1 Search strategy for randomized trials and observational studies reporting outcome following treatment for twin-twin transfusion syndrome Table S2 Characteristics of studies included in systematic review Table S3 Inconsistency in outcome reporting across randomized trials and 20 largest observational studies evaluating outcome following treatment for twin-twin transfusion syndrome Informe de resultados de ensayos aleatorizados y estudios observacionales de evaluación de tratamientos para el síndrome de transfusión feto-fetal: revisión sistemática RESUMEN Objetivo El síndrome de transfusión feto-fetal (TTTS, por sus siglas en inglés) está asociado a una mortalidad y morbilidad significativas. Los posibles tratamientos para esta condición requieren una evaluación rigurosa. El objetivo de este estudio fue evaluar informes sobre los resultados de estudios observacionales y ensayos controlados aleatorizados que evaluaron tratamientos para el TTTS.
Métodos Se realizaron búsquedas en el Registro Central Cochrane de Ensayos Controlados, EMBASE y MEDLINE, desde su inicio hasta agosto de 2016. Se incluyeron los estudios observacionales y los ensayos controlados aleatorizados que informaban sobre el resultado después del tratamiento para el TTTS en embarazos gemelares de carácter monocorial-biamniótico y en embarazos triples de tipo monocorial-triamniótico o bicorial-triamniótico. El informe de resultados se extrajo y se categorizó de forma sistemática.
Resultados Se incluyeron seis ensayos aleatorizados y 94 estudios observacionales, que reportaban datos de 20071 madres y 3199 niños. Se evaluaron seis tratamientos diferentes. Los estudios incluidos informaban sobre 62 resultados diferentes, a saber: seis fetales, siete de mortalidad de progenie, 25 neonatales, seis de la primera infancia y 18 materno-operativos. Los resultados se habían reportado de manera no uniforme entre ensayos. Por ejemplo, al considerar la mortalidad de la progenie, 31 (31%) estudios reportaron nacimientos vivos, 31 (31%) la muerte intrauterina, 49 (49%) la mortalidad neonatal y 17 (17%) la mortalidad perinatal. Cuatro (4%) estudios reportaron el síndrome de dificultad respiratoria. Solo 19 (19%) estudios habían sido diseñados para un seguimiento a largo plazo y 11 (11%) de estos reportaron parálisis cerebral.
Conclusiones Los estudios que evalúan los tratamientos para el TTTS a menudo no han reportado resultados clínicamente importantes, en particular los resultados de morbilidad neonatal, y la mayoría no fueron diseñados para un seguimiento a largo plazo. El desarrollo de un conjunto de resultados esenciales podría ayudar a estandarizar la recopilación de resultados y los informes de los estudios sobre el TTTS.
